Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner - Novo Nordisk (NYSE:NVO)

Novo Nordisk A/S (NYSE: NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs, 

Related Keywords

Viatris Inc ,Novo Nordisk ,Novo Wegovy ,Mylan Pharmaceuticals ,Reuters ,Us Patent Office ,Big Pharma ,Weight Loss Drugs ,Snacking Industry ,Who Will ,